Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
B-cell epitopes of grass pollen allergens are specific regions on major allergen proteins (such as Phl p 1 and Phl p 5 from timothy and group 5/6 grass pollen allergens) that are recognized by the variable domains of B-cell receptors and antibodies, predominantly IgE and IgG. They can be linear (continuous sequences of amino acids) or conformational (spatially proximate residues defined by 3D structure), and their recognition by IgE leads to allergic sensitization and symptoms, while their targeting by IgG (via immunotherapy or vaccination) can block IgE binding and induce tolerance. Mapping and modifying these epitopes provides the basis for developing safer and more effective allergy vaccines and diagnostics, as well as understanding molecular mechanisms of immunity and hypersensitivity in grass pollen allergy.
Induction of blocking antibodies (IgG) to compete with IgE for allergen binding; Reduction of allergic sensitization by desensitization (tolerization to allergen via exposure); Inhibition of IgE-mediated allergic responses (by outcompeting or blocking IgE-allergen interactions)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on B-cell epitope of grass pollen allergen.